Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **carboplatin**, a platinum-based chemotherapy drug, and **pembrolizumab**, a monoclonal antibody that acts as a PD-1 inhibitor. Pembrolizumab works by blocking the PD-1 receptor on T-cells, enhancing the immune response against cancer cells. Carboplatin is used to kill cancer cells by interfering with DNA replication. The combination is used in the treatment of various cancers, including non-small cell lung cancer (NSCLC).
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + pembrolizumab.